Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MEDI8852 in Healthy Adults
NCT02350751Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Influenza A (IAV) comparing MEDI8852 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852 at 100 days. Started Jan 2015; status: completed.
02
Drugs
MEDI8852
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02350751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350751.